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Abstract The interaction between Alzheimer amyloid peptide 
Aß(l -40) and membrane lipids was studied by circular dichroism 
spectroscopy under the conditions of physiologically relevant 
ionic strength and neutral pH. The peptide binds to the 
membranes containing ganglioside G M 1 and upon binding 
undergoes a conformational transition from random coil to an 
ordered structure rich in ß-sheet. This interaction appears to be 
ganglioside-speciflc as no changes in Aß(l -40) conformation 
were found in the presence of various phospholipids or 
sphingomyelin. The isolated oligosaccharide moiety of the 
ganglioside was ineffective in inducing alterations in the 
secondary structure of Aß(l-40) . No interaction was observed 
between ganglioside GM i and the N-terminal peptide fragment 
Aß(l-28) . Binding to the ganglioside is likely to modulate the 
neurotoxic and/or amyloidogenic properties of Aß(l-40) . 
Key words: ß-Amyloid peptide; Alzheimer's disease; 
Ganglioside G M I ; Peptide conformation 
1. Introduction 
A key pathological feature of Alzheimer's disease (AD) is 
the formation and progressive deposition of insoluble amyloid 
fibrils in brain parenchyma and in the walls of cerebral and 
meningeal blood vessels [1]. The principal component of amy-
loid deposits is the ~ 4 k D a amyloid ß-peptide (Aß) [2,3], a 
product of proteolytic processing of a much larger amyloid 
precursor protein (APP) encoded by a gene on chromosome 
21 [4]. The role of Aß in the pathogenesis of A D is suggested 
by the findings that specific mutat ions in APP (in close prox-
imity to the amino- or carboxyl-terminus of A ß or within the 
Aß region) are linked to familial forms of A D [5-7]. A link 
between Aß and A D neuropathological lesions is also indi-
cated by the findings that fibrillar Aß is toxic to neuronal cells 
in culture [8-10]. However, the molecular mechanisms of the 
neurotoxic action of the peptide remain largely unknown. 
A growing number of observations indicate that Aß may 
alter the physicochemical properties of neuronal membranes, 
including membrane fluidity [11] and the permeability to ions 
and nonelectrolytes [12-18]. These findings strongly suggest 
that at least some of the pathophysiological effects of A ß 
may be mediated by peptide-membrane interactions. Interest 
in the interaction between Aß and the constituents of brain 
membranes has been further stimulated by the recent identi-
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fication of a ganglioside G M I - b o u n d form of Aß as an impor-
tant component of early diffuse plaques in A D brain [19]. In 
this communication, we explore the molecular mechanism of 
the interaction between Aß and the lipid components of bio-
logical membranes. Using circular dichroism spectroscopy, 
our data demonstrate that Aß(l^lO) binds to model mem-
branes containing ganglioside G M I and upon binding under-
goes a major conformational transition. This effect appears to 
be ganglioside-speciflc as under the conditions of physiologi-
cally relevant ionic strength, no changes in Aß conformation 
could be detected in the presence of ganglioside-free vesicles 
composed of zwitterionic or acidic phospholipids. 
2. Materials and methods 
2.1. Materials 
The peptides were obtained from Bachern California Inc. (Torrance, 
CA) [Aß(l-40), lot 506063] or American Peptide Company (Sunny-
vale, CA) [Aß(1^0), lot K01047A1; Aß(l-28), lot H02022T1]. The 
purity of the peptides was greater than 98%. l-Palmitoyl-2-oleoyl 
phosphatidylcholine, l-palmitoyl-2-oleoyl phosphatidylglycerol and 
1 -palmitoyl-2-oleoyl phosphatidylserine were purchased from Avanti 
Polar Lipids (Alabaster, AL). Ganglioside GMI was obtained from 
Calbiochem (La Jolla, CA) and sphingomyelin from Sigma (St. Louis, 
MO). The pentasaccharide portion of ganglioside GMI (II3NeuAc-
GgOse.i) was obtained from BioCarb Chemicals (Lund, Sweden). 
Prior to the experiments, the peptides were dissolved to 1 mg/ml in 
HFIP (Sigma) and stored at —20°C. As reported previously [20], the 
treatment with HFIP breaks up any aggregates of Aß and thus allows 
for normalization of the properties of different preparations of the 
peptide. 
2.2. Preparation of lipid vesicles 
To obtain small unilamellar vesicles, lipid films of a desired com-
position were dispersed by vortexing in 10 mM phosphate buffer, pH 
7.4. The resulting mixture of multilamellar liposomes was then soni-
cated in an ice bath for approximately 15 min using a probe-type 
sonifier. Metal debris from the titanium tip of the probe was removed 
by centrifugation for several minutes in a microfuge. Vesicles were 
kept at room temperature and used within a few hours after prepara-
tion. 
2.3. Circular dichroism spectroscopy 
Aqueous peptide solutions for circular dichroism measurements 
were prepared by evaporating the organic solvent from the stock 
peptide solution in HFIP and redissolving the resulting peptide film 
in buffer. The solutions were used within 3 h after preparation. The 
interaction of Aß peptides with lipids was studied by following 
changes in circular dichroism spectra upon the addition of small ali-
quots of a suspension of lipid vesicles or micellar ganglioside to 25 
|iM peptide solution in buffer. Circular dichroism spectra were ac-
quired on a JASCO J-600 spectropolarimeter at room temperature 
using a 1 mm quartz cell. Typically, four spectra were averaged and 
smoothed to improve signal to noise ratio. To correct for the contri-
bution of lipid to circular dichroism spectra, the signal of pure lipid at 
appropriate concentration was subtracted from the signal of peptide-
lipid samples. This method of subtracting the lipid contribution was 
valid since for those compounds that possess strong CD signal but 
failed to interact with the peptide (sphingomyelin, GMi-oligosacchar-
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ide), subtraction yielded essentially an identical spectrum to that of 
the peptide alone (see Section 3). 
3. Results 
The effect of various lipids on the backbone conformation 
of Aß peptides was studied by far-UV circular dichroism spec-
troscopy. The spectrum of a freshly prepared solution of 
Aß(l-40) in 10 mM phosphate buffer has a minimum at ap-
proximately 197 nm and is characteristic of an essentially 
random conformation [21]. Under the conditions of our ex-
periments, the above spectrum remained unchanged for at 
least 8 h, indicating the preservation of an unordered (mono-
meric) structure of the peptide. Upon solubilization in water, 
ganglioside GMI is known to form micelles [22]. Addition of 
micellar ganglioside to the solution of Aß(l^tO) resulted in a 
rapid change in the peptide CD spectrum (Fig. 1A). The effect 
was concentration dependent and appeared to saturate at a 
ganglioside to peptide molar ratio of approximately 20:1 (ac-
curate determination of the saturation point was hampered by 
a rapid deterioration of the signal to noise ratio in CD spectra 
at high lipid concentration). The spectrum of Aß(l^tO) in the 
presence of a 18-fold molar excess of ganglioside GMI has a 
minimum at approximately 217 nm and a maximum at 197 
nm, the features characteristic of an ordered, predominantly 
ß-sheet conformation [21]. The above spectrum remained un-
changed for many hours after formation of the peptide-lipid 
complex. In order to assess the role of electrostatic effects in 
the interaction between Aß(1^10) and ganglioside GMI, the 
circular dichroism measurements described above were re-
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Fig. 1. Circular dichroism spectra of 25 uM Aß(1^40) alone (solid 
line) and in the presence of various concentrations of ganglioside 
GMI- The ganglioside:peptide molar ratios are: 5:1 (dashed line), 
10:1 (dotted line) and 18:1 (dash-dotted line). A: 10 mM phosphate 
buffer, pH 7.4. B: 10 mM phosphate buffer, 100 mM NaF, pH 7.4. 
Spectra were corrected by subtracting the contribution of lipid 
alone. 
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Fig. 2. Circular dichroism spectra of 25 |iM Aß(1^10) alone (solid 
line) and in the presence of POPC:ganglioside GMi (3:1) vesicles. 
The ganglioside:peptide molar ratios are: 2.5:1 (dashed line), 5:1 
(dotted line), 7:1 (dash-dotted line) and 9:1 (dash-double dotted 
line). The measurements were performed in 10 mM phosphate buf-
fer, 100 mM NaF, pH 7.4. Spectra were corrected by subtracting 
the contribution of lipid alone. 
peated in the presence of 100 mM NaF (sodium fluoride 
was used instead of NaCl to avoid problems associated with 
high far-UV absorption of the latter salt). As shown in Fig. 1, 
very similar ganglioside-induced transitions in Aß conforma-
tion were observed in the presence and absence of NaF. Sim-
ilar results were also obtained in a buffer containing 100 mM 
sodium phosphate (data not shown for brevity). Furthermore, 
the spectrum characteristic of ganglioside GMI-bound peptide 
was preserved upon increasing the salt concentration to 200 
mM. 
Changes in CD spectra indicative of the unordered struc-
ture —> ß-sheet transition were also observed when Aß(1^10), 
in high ionic strength buffer (10 mM phosphate, 100 mM 
NaF), was titrated with unilamellar vesicles composed of 
POPC and 25 mol% of ganglioside GMI (Fig. 2). The above 
effect is apparently ganglioside-specific as no changes in the 
peptide CD spectrum (in the same buffer) were detected in the 
presence of ganglioside-free POPC membranes, vesicles com-
posed of acidic phospholipids such as POPG and POPS, or 
those containing sphingomyelin (spectra not shown for brev-
ity). An alternative procedure was also used to increase the 
ganglioside to peptide molar ratio. In these experiments, dif-
ferent aliquots of Aß(1^10) solution were incubated with ves-
icles containing a constant amount of POPC and increasing 
proportions of ganglioside GMI • At corresponding ganglioside 
to peptide ratios, results essentially identical to those shown in 
Fig. 2 were obtained (data not shown). Furthermore, no un-
ordered -> ß-sheet transition occurred in the presence of even a 
large molar excess of the isolated oligosaccharide moiety of 
ganglioside GMI (Fig. 3). This clearly indicates that both the 
sugar head group and the hydrocarbon portion of the gan-
glioside are required to bring about a conformational transi-
tion in Aß(1^10). 
Aß(l-40) has an amphiphilic character. The N-terminal 
portion of the peptide is relatively polar and contains a num-
ber of charged residues, while the C-terminal region is highly 
hydrophobic. In order to determine which part of Aß(l^-O) is 
involved in ganglioside GMI binding, the experiments de-
scribed above were repeated with the peptide fragment 
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Fig. 3. Circular dichroism spectra of 25 uM Aß(1^40) alone (solid 
line) and in the presence of Gim-oligosaccharide at an oligosacchar-
ide: peptide molar ratio of 19:1 (dashed line). The measurements 
were performed in 10 mM phosphate buffer, 100 mM NaF, pH 7.4. 
Spectra were corrected by subtracting the contribution of the oligo-
saccharide alone. 
Aß(l-28). Previous studies have demonstrated that the frag-
ment Aß(l-28) forms amyloid-like fibrils of a morphology 
similar to those found in AD brain [23,24]. As shown in 
Fig. 4, the addition of ganglioside GMI to Aß(l-28) solution 
in buffer (10 mM phosphate, 100 mM NaF) did not result in 
any changes in the CD spectrum of the peptide. 
4. Discussion 
Apparently conflicting reports have been published regard-
ing the CD spectra of soluble Aß(l^-O) in aqueous buffer. 
While some authors have reported spectra indicative of a 
mixture of random coil and ß-sheet conformations [25,26], 
the spectra obtained by others are characteristic of an essen-
tially pure random coil structure [27,28]. These discrepancies 
likely reflect different propensities of various peptide prepara-
tions to self-associate (e.g. as a result of the presence of dif-
ferent amounts of aggregated 'seeds' which promote the self-
association process [29,30]). Indeed, our present results show 
that upon complete disaggregation of the peptide by HFIP 
treatment [20], Aß(l^-O) at low concentration in aqueous so-
lution adopts a random conformation with no indication of ß-
sheet structure. The above conformation (and thus the mono-
meric state of the peptide) remains stable for many hours. 
The key observation of the present study is the finding that 
Aß(l^lO) binds to micellar ganglioside GMI or ganglioside 
GMI-containing membrane vesicles, and as a result of this 
binding, undergoes a rapid transition to an ordered conforma-
tion characterized by a high content of ß-sheet structure. A 
similar conformational transition of Aß(l^-O) was recently 
observed in the presence of the model acidic phospholipid 
phosphatidylglycerol [28]. However, peptide binding to the 
latter lipid appears to be purely electrostatic; it is completely 
inhibited in the presence of 100 mM NaCl [28] or 100 mM 
NaF. This may be contrasted with the interaction between 
Aß(l^lO) and ganglioside GMI which shows very little sensi-
tivity to the ionic strength of the buffer. The notion that 
electrostatic effects do not play a dominant role in Aß( l -
40)-ganglioside binding is further indicated by the experiments 
with a highly charged peptide fragment Aß(l-28). The appar-
ent lack of interaction between the latter peptide and ganglio-
side GMI suggests that the apolar C-terminal region of Aß( l -
40) is crucial for ganglioside binding. 
We have also tested a number of other lipids, including 
acidic phosphatidylserine as well as zwitterionic phosphatidyl-
choline and sphingomyelin. Under the conditions of physio-
logically relevant ionic strength (100 mM NaF or 100 mM 
sodium phosphate), none of the above lipids was able to in-
duce any conformational transition in Aß(l^lO). Therefore, 
the effect described in this study appears to be ganglioside-
specific. The roles of individual chemical groups of ganglio-
side molecule in the interaction with Aß remain to be eluci-
dated; some light in this respect should be shed by the on-
going experiments with ganglioside variants of different head 
group structure. Nevertheless, it is striking that no changes in 
Aß(l^lO) conformation could be detected in the presence of 
the isolated oligosaccharide moiety of ganglioside GMI- This 
strongly suggests that the membrane (or micellar) surface is 
required to bring about a conformational transition in the 
peptide. The transition to an ordered (largely ß-sheet) struc-
ture may be facilitated by the interfacial environment of the 
lipid head group region, surface-induced aggregation of the 
peptide, partial penetration into the hydrocarbon region, or 
the combination of these factors. 
The present findings are likely to be of direct relevance to 
the neurotoxic action of Aß. While present only in relatively 
small quantities in most tissues, gangliosides are abundant 
components of nervous tissue [31,32]. Ganglioside GMI tends 
to accumulate in certain regions of neurons, especially in syn-
aptic membranes [32,33]. We propose that the specific inter-
action of Aß with ganglioside-rich domains of neuronal mem-
branes may result in a local membrane perturbation. This, in 
turn, could trigger a cascade of events that eventually lead to 
neuronal cell death. Another potential role of gangliosides in 
the pathology of AD has been recently suggested by Yaniga-
sawa et al. [19] and Selkoe [34]. Based on the observation that 
ganglioside GMI-bound Aß is associated with early diffuse 
plaques [19], these authors have hypothesized that ganglio-
side-bound peptide may act as a 'seed' that facilitates forma-
o a 
-0 
ÖJ3 
© 
2000 
0 
-2000 
-4000 
-6000 
-8000 
12000 
14000 
-
r / ' 
/f 
/ / 
// 
J! 
_ ^ ^ ^ ~ 
' 
200 210 220 230 240 
Wavelength (nm) 
250 
Fig. 4. Circular dichroism spectra of 25 uM Aß(l-28) (solid line) 
alone and in the presence of ganglioside GMi at a ganglioside:pep-
tide molar ratio of 18:1 (dashed line). The measurements were per-
formed in 10 mM phosphate buffer, 100 mM NaF, pH 7.4. The 
spectrum in the presence of ganglioside GMI was corrected by sub-
tracting the contribution of lipid alone. 
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tion of a mature amyloid plaque. The above hypothesis re-
mains to be tested. Nevertheless, the finding that ganglioside 
G M I binding to Aß results in peptide conformational transi-
tion to a (presumably intermolecular) ß-sheet structure is 
strongly supportive of the general idea that gangliosides 
may play an important role by modulating the amyloidogenic 
properties of Aß . 
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